# New Insights into the Bioenergetic and Immunomodulatory Properties of Phospholipases A2 from Bothrops diporus Venom

**Authors:** Daniela J. Sasovsky, Ana K. Oliveira, Dilza Trevisan Silva, Gonzalo A. Ojeda, Cristopher Almarza, Bruno Lomonte, Jay W. Fox, Félix A. Urra, Soledad Bustillo

PMC · DOI: 10.3390/toxins18020114 · Toxins · 2026-02-23

## TL;DR

This study explores how snake venom phospholipases affect cancer cell energy and immune responses, revealing new therapeutic potential.

## Contribution

The first integrated analysis of Bothrops diporus PLA2s' effects on mitochondrial function and immune modulation.

## Key findings

- B. diporus PLA2s induce mitochondrial stress in breast cancer cells, reducing proliferation.
- PLA2s trigger a dynamic cytokine response in human immune cells, including early cytotoxic and late regulatory mediators.
- A specific PLA2 isoform uniquely activates IL-10 and CCL20, highlighting isoform-specific immunomodulatory effects.

## Abstract

Phospholipases A2 (PLA2s) are key mediators of the cytotoxic and inflammatory activities of snake venoms. While PLA2 isoforms from Bothrops diporus venom have been characterized and shown to possess antimetastatic and antiangiogenic properties, their impact on mitochondrial bioenergetics and immune modulation has not yet been investigated. In this study, we examined the bioenergetic and immunomodulatory effects of B. diporus PLA2s using integrated biochemical, metabolic, and multiplex cytokine analyses. In MDA-MB-231 breast cancer cells, pooled PLA2s induced a dose-dependent decrease in MTT-reducing activity, increased mitochondrial ROS, caused Δψm hyperpolarization, and decreased NADH autofluorescence, collectively indicating sustained mitochondrial stress. Real-time impedance measurements further revealed a marked inhibition of cell proliferation. In human PBMCs, pooled PLA2s elicited a dynamic cytokine program, inducing early cytotoxic (Granzyme B) and chemotactic (CCL2, CCL3, CCL4) mediators, followed by late pro-inflammatory and regulatory factors such as IL-6, TNF-β, IL-10 and IL-15. Analysis of a single purified PLA2 isoform (Fraction 6) confirmed activation of the canonical IL-6/TNF-α/IL-1β axis but uniquely induced IL-10 and CCL20, revealing isoform-specific immunomodulatory properties. Altogether, these findings provide the first integrated characterization of mitochondrial and immune perturbations induced by B. diporus PLA2s, expanding their recognized biological scope and underscoring their potential as molecular templates for novel pharmacological strategies targeting mitochondrial vulnerabilities or modulating the tumor immune microenvironment.

## Linked entities

- **Genes:** CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347], CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348], CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 6351], IL6 (interleukin 6) [NCBI Gene 3569], LTA (lymphotoxin alpha) [NCBI Gene 4049], IL10 (interleukin 10) [NCBI Gene 3586], IL15 (interleukin 15) [NCBI Gene 3600], IL1B (interleukin 1 beta) [NCBI Gene 3553], CCL20 (C-C motif chemokine ligand 20) [NCBI Gene 6364]
- **Proteins:** PLA2G2A (phospholipase A2 group IIA)
- **Diseases:** breast cancer (MONDO:0004989)
- **Species:** Homo sapiens (taxon 9606)

## Full-text entities

- **Genes:** VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}, PLA2G2A (phospholipase A2 group IIA) [NCBI Gene 5320] {aka MOM1, PLA2, PLA2B, PLA2L, PLA2S, PLAS1}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, CCL20 (C-C motif chemokine ligand 20) [NCBI Gene 6364] {aka CKb4, Exodus, LARC, MIP-3-alpha, MIP-3a, MIP3A}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, IL31 (interleukin 31) [NCBI Gene 386653] {aka IL-31}, IL27 (interleukin 27) [NCBI Gene 246778] {aka IL-27, IL-27A, IL27A, IL27p28, IL30, p28}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, IL25 (interleukin 25) [NCBI Gene 64806] {aka IL17E}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CCL2 (C-C motif chemokine ligand 2) [NCBI Gene 6347] {aka GDCF-2, HC11, HSMCR30, MCAF, MCP-1, MCP1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, IFNL2 (interferon lambda 2) [NCBI Gene 282616] {aka IFNL2a, IFNL3a, IL-28A, IL28A}, IL22 (interleukin 22) [NCBI Gene 50616] {aka IL-21, IL-22, IL-D110, IL-TIF, ILTIF, TIFIL-23}, IL9 (interleukin 9) [NCBI Gene 3578] {aka HP40, IL-9, P40}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, IL21 (interleukin 21) [NCBI Gene 59067] {aka CVID11, IL-21, Za11}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}, CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 6351] {aka ACT2, AT744.1, G-26, HC21, LAG-1, LAG1}, LTA (lymphotoxin alpha) [NCBI Gene 4049] {aka LT, TNFB, TNFSF1, TNLG1E}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, IL5 (interleukin 5) [NCBI Gene 3567] {aka EDF, IL-5, TRF}, IL7 (interleukin 7) [NCBI Gene 3574] {aka IL-7, IMD130}, IL17F (interleukin 17F) [NCBI Gene 112744] {aka CANDF6, IL-17F, ML-1, ML1}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, IL23A (interleukin 23 subunit alpha) [NCBI Gene 51561] {aka IL-23, IL-23A, IL23P19, P19, SGRF}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, CXCL10 (C-X-C motif chemokine ligand 10) [NCBI Gene 3627] {aka C7, IFI10, INP10, IP-10, SCYB10, crg-2}, IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}
- **Diseases:** neurotoxic (MESH:D020258), Cancer (MESH:D009369), mitochondrial disturbances (MESH:D028361), inflammation (MESH:D007249), injury to (MESH:D014947), myotoxic (MESH:D000081030), inflammatory cytokines (MESH:D000080424), breast cancer (MESH:D001943), triple-negative breast cancer (MESH:D064726), cytotoxic (MESH:D064420), metastasis (MESH:D009362)
- **Chemicals:** FCCP (MESH:D002259), ACN (MESH:C084683), SDS (MESH:D012967), free fatty acids (MESH:D005230), tetramethylrhodamine methyl ester (MESH:C401833), phospholipid (MESH:D010743), acetonitrile (MESH:C032159), streptomycin (MESH:D013307), prostaglandins (MESH:D011453), glycerophospholipids (MESH:D020404), Formazan (MESH:D005562), pyruvate (MESH:D019289), Menadione (MESH:D024483), Trypan Blue (MESH:D014343), DMSO (MESH:D004121), Glucose (MESH:D005947), MitoSOX (MESH:C521281), ROS (MESH:D017382), NADH (MESH:D009243), PBS (MESH:D007854), lipid (MESH:D008055), thromboxanes (MESH:D013931), glutamine (MESH:D005973), CO2 (MESH:D002245), TFA (MESH:D014269), CHCA (MESH:C007175), leukotrienes (MESH:D015289), MTT (MESH:C070243), penicillin (MESH:D010406), lysophospholipids (MESH:D008246), eicosanoid (MESH:D015777), DMEM (-)
- **Species:** Bothrops jararacussu (jararacussu, species) [taxon 8726], Mus musculus (house mouse, species) [taxon 10090], Crotalus durissus terrificus (cascabel, subspecies) [taxon 8732], Bothrops leucurus (species) [taxon 157295], Bothrops atrox (barba amarilla, species) [taxon 8725], Homo sapiens (human, species) [taxon 9606], Bothrops jararaca (jararaca, species) [taxon 8724], Bothrops diporus (species) [taxon 1107943]
- **Cell lines:** MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12945160/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12945160/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12945160/full.md

---
Source: https://tomesphere.com/paper/PMC12945160